The research program ILP101 Inhale receives funding for in vivo proof-of-concept testing from The Swedish Cystic Fibrosis Association

The program ILP101 (L. reuteri expressing the mucosal chemokine CXCL17)-Inhale is developed to treat lung infections with MDR pathogens in the rare diseases SAVI and CF, and in extension for all people with pneumonia, aiming to preserve lung function and be a complement to traditional antibiotics.

This grant is given to Prof Mia Phillipson at Uppsala University to support the collaborative program initiated with a Marie Skłodowska-Curie Actions Award where Ilya Pharma and Uppsala University are partners.